Cipher Pharmaceuticals Inc. (CPH.TO)
| Previous Close | 18.22 |
| Open | 12.20 |
| Bid | 15.59 x 0 |
| Ask | 15.64 x 0 |
| Day's Range | 11.52 - 16.23 |
| 52 Week Range | 4.10 - 19.69 |
| Volume | |
| Avg. Volume | 48,753 |
| Market Cap | 401.997M |
| Beta (5Y Monthly) | 1.25 |
| PE Ratio (TTM) | 12.88 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- CNW Group
Cipher Pharmaceuticals Partner Moberg Pharma AB Provides Update on MOB-015 Phase 3 Study
Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") announced today that its partner, Moberg Pharma AB ("Moberg"), issued a news release earlier today stating that it has received information about clinical cure in a subset of patients in the ongoing North American Phase 3 study for MOB-015, a product for the treatment of nail fungus. Moberg has noted that the number of patients who have achieved clinical cure in this blinded subset of patients is lower than its exp
- CNW Group
Cipher Pharmaceuticals Reports Second Quarter 2024 Results
Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") today announced its financial and operating results for the three and six months ended June 30, 2024.
- CNW Group
Cipher Pharmaceuticals Schedules Q2 2024 Earnings Release and Conference Call
Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") today announced that it will release its financial results for the second quarter of 2024 after the market close on Thursday, August 8, 2024. The Company will also hold a conference call on Friday, August 9, 2024 at 8:30AM ET to discuss the results and corporate developments.
